Obstructive sleep apnea promotes the progression of lung cancer by modulating cancer cell invasion and cancer-associated fibroblast activation via TGFβ signaling.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 9511366 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-2928 (Electronic) Linking ISSN: 13510002 NLM ISO Abbreviation: Redox Rep Subsets: MEDLINE

Publication: 2016- : Abingdon : Taylor & Francis
Original Publication: Edinburgh ; New York : Churchill Livingstone, c1994-

Lung Neoplasms*/metabolism ; Cancer-Associated Fibroblasts*/metabolism ; Cancer-Associated Fibroblasts*/pathology ; Sleep Apnea, Obstructive*/metabolism ; Sleep Apnea, Obstructive*/pathology; Humans ; Animals ; Mice ; Transforming Growth Factor beta/metabolism ; Neoplasm Invasiveness/pathology ; Hypoxia ; Cell Line, Tumor

Objective: Obstructive sleep apnea (OSA) is associated with severity of pneumonia; however, the mechanism by which OSA promotes lung cancer progression is unclear.
Methods: Twenty-five lung cancer patients were recruited to investigate the relationship between OSA and cancer-associated fibroblast (CAFs) activation. Lung cancer cells (A549) and WI38 fibroblast cells were used to explore the hypoxia-induced TGFβ expression using qPCR, Western blot, and ELISA. Wound healing and transwell assays were performed to evaluate cancer cell migration and invasion. A549 or A549-Luc + WI38 xenograft mouse models were established to detect the intermittent hypoxia (IH) associated with lung tumor growth and epithelial-mesenchymal transition (EMT) in vivo .
Results: OSA promotes CAF activation and enrichment in lung cancer patients. Hypoxia (OSA-like treatment) activated TGFβ signaling in both lung cancer cells and fibroblasts, which promoted cancer cell migration and invasion, and enriched CAFs. IH promoted the progression and EMT process of lung cancer xenograft tumor. Co-inoculation of lung cancer cells and fibroblast cells could further promote lung cancer progression.
Conclusions: IH promotes lung cancer progression by upregulating TGFβ signaling, promoting lung cancer cell migration, and increasing the CAF activation and proportion of lung tumors.

Chest. 2014 Oct;146(4):982-990. (PMID: 24831859)
Oncol Rep. 2012 Aug;28(2):659-67. (PMID: 22664743)
Cell Cycle. 2019 Sep;18(17):2141-2156. (PMID: 31339433)
N Engl J Med. 1993 Apr 29;328(17):1230-5. (PMID: 8464434)
BMJ. 2014 Jun 17;348:g3745. (PMID: 24939874)
Mech Dev. 2001 Nov;109(1):13-26. (PMID: 11677049)
Trends Pharmacol Sci. 2018 Jan;39(1):59-74. (PMID: 29153879)
Nat Rev Dis Primers. 2015 Jun 25;1:15015. (PMID: 27188535)
Nat Rev Cancer. 2013 Nov;13(11):788-99. (PMID: 24132110)
Am J Respir Crit Care Med. 2012 Jul 15;186(2):190-4. (PMID: 22610391)
Cancer Lett. 2021 Nov 1;520:222-232. (PMID: 34363903)
Biomolecules. 2020 Dec 12;10(12):. (PMID: 33322749)
J Thorac Dis. 2015 May;7(5):920-9. (PMID: 26101650)
Multidiscip Respir Med. 2019 Feb 14;14:8. (PMID: 30809382)
Int J Obes (Lond). 2020 Aug;44(8):1653-1667. (PMID: 32071426)
Am J Epidemiol. 2013 May 1;177(9):1006-14. (PMID: 23589584)
Sleep Med Disord. 2017;1(4):. (PMID: 29517065)
Oncogene. 2021 Jun;40(24):4151-4166. (PMID: 34050266)
Physiol Rev. 2021 Jan 1;101(1):147-176. (PMID: 32466724)
PLoS One. 2016 Apr 06;11(4):e0152749. (PMID: 27050437)
Cell. 2005 Mar 25;120(6):831-42. (PMID: 15797383)
Cells. 2019 Sep 20;8(10):. (PMID: 31547193)
Development. 2014 Feb;141(3):502-13. (PMID: 24449833)
Oncogene. 2014 Mar 27;33(13):1649-57. (PMID: 23624917)
Chest. 2016 Aug;150(2):451-63. (PMID: 27164292)
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5931-5937. (PMID: 32127478)
PLoS One. 2014 Jan 21;9(1):e86326. (PMID: 24466027)
Med J Islam Repub Iran. 2013 Aug;27(3):161-2. (PMID: 24791128)
Lancet Respir Med. 2015 Apr;3(4):310-8. (PMID: 25682233)
Int J Oncol. 2015 Mar;46(3):933-43. (PMID: 25573346)
Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1323-31. (PMID: 23946285)
Cancer Gene Ther. 2021 Sep;28(9):984-999. (PMID: 33712707)

Keywords: CAFs; OSA; TGFβ; cancer progression; inflammation; intermittent hypoxia; lung cancer; migration

0 (Transforming Growth Factor beta)

Date Created: 20231127 Date Completed: 20231129 Latest Revision: 20240410

20240410

PMC11001276

10.1080/13510002.2023.2279813

38010093